Aptatek Company Spotlight: Bringing PKU Testing Home

Aptatek BioSciences is building a connected diagnostic system for a problem medicine has tolerated for too long: patients can collect a blood sample at home, yet the answer may still have to travel through a central laboratory before it becomes useful.

The Princeton, New Jersey company is developing PheCheck, an investigational system designed to measure phenylalanine from a fingerstick sample in about 20 minutes. PheCheck is Aptatek’s first application of HomeCheck, a DNA-aptamer platform for quantitative small-molecule monitoring outside the central lab.

CEO and President Michael Boyce-Jacino leads the company with co-founders Tilla Worgall, MD, PhD, and Milan Stojanovic, PhD, whose Columbia University research produced the underlying sensing technology. The immediate market is phenylketonuria, or PKU, a rare inherited disorder that can require lifelong control of blood phenylalanine.

Why Aptatek matters now is not complicated. Healthcare keeps moving services into the home, but useful care still depends on getting trustworthy measurements at the right time. Aptatek is trying to close that gap without pretending regulation, clinical validation, or manufacturing can be skipped.

From Columbia Science to a Patient-First Diagnostic

Aptatek grew out of DNA-aptamer research developed in the Columbia University Medical Center laboratories of Worgall and Stojanovic. Aptamers are short nucleic-acid sequences selected to bind specific molecular targets. In Aptatek’s case, the goal is to detect small molecules that are difficult to measure with conventional antibody-based tests.

That scientific origin gives Aptatek a defensible starting point, but university science is only the opening argument. A diagnostic company must turn molecular recognition into a repeatable cartridge, a reliable reader, useful software, clinical evidence, regulated manufacturing, and a workflow that patients and care teams can actually live with. The gap between an elegant paper and a cleared device has swallowed plenty of good ideas.

Aptatek has built PheCheck around that full system. A patient uses a fingerstick sample and single-use cartridge. A reusable, battery-powered reader analyzes the sample, while a connected application is designed to display results, track trends, and share information with an authorized care team. The product remains investigational and is not available for sale.

Why PheCheck Matters for PKU

People living with PKU cannot properly metabolize phenylalanine, an amino acid found in protein. Management can involve a carefully controlled diet, medication, and regular monitoring. Yet current testing often relies on dried blood spots mailed to centralized laboratories, which creates a delay between the moment a sample is collected and the moment a patient or clinician can act on the result.

PheCheck is designed to compress that delay. Aptatek describes a roughly 20-minute result, compared with the multi-day turnaround associated with traditional sample transport and lab processing. Faster is not automatically better medicine, but timely quantitative information could make trends easier to see between clinic visits and could reduce the amount of decision-making done in the dark.

The product also reflects direct market discovery. Aptatek says 1,065 PKU patients and caregivers responded within 48 hours to a home-testing survey conducted through the National PKU Alliance. That is first-party research, not a commercial adoption metric. It still shows a company testing its assumptions with the community expected to use the product.

Clinical Validation Comes Before the Victory Lap

PheCheck has received FDA Breakthrough Device designation and is being evaluated in a multi-site clinical study. Breakthrough designation can improve communication with the FDA and prioritize review. It does not mean a device is cleared, approved, clinically proven, or ready for sale.

Aptatek identifies Boston Children’s Hospital, Ann & Robert H. Lurie Children’s Hospital of Chicago, and UPMC as clinical-study sites. The company is targeting a 510(k) submission in late 2026 and a U.S. launch in early 2027, both subject to study outcomes and FDA clearance. Until those gates are passed, the correct posture is interest with discipline, not confetti.

The distinction matters because diagnostics companies sell confidence before they sell hardware. PheCheck must demonstrate that results are accurate and reliable across the people, samples, environments, and edge cases it is meant to serve. The current study is the bridge between Aptatek’s promising platform and a product clinicians can use.

The Team and Capital Behind Aptatek

Boyce-Jacino brings more than three decades of diagnostics and life-sciences operating experience, according to Aptatek. Worgall is a Columbia professor and metabolic-disease clinician. Stojanovic is a Columbia professor whose work spans molecular recognition, biosensing, and diagnostics. Their combination gives Aptatek scientific depth, clinical context, and company-building experience at a stage when all three are required.

The capital history also reveals the operating model. Aptatek raised a $4 million Seed round in 2022 led by IP Group, with Canterbury Scientific and the National PKU Alliance participating. It later announced an undisclosed funding tranche in 2024, bridge financing in 2025, and an undisclosed initial close in September 2026 led by Canterbury Scientific and Longview Innovation. Because several amounts remain private, no reliable total-funding number should be claimed.

Those backers are more than logos on a slide. Canterbury brings diagnostics manufacturing and quality-control experience. Longview invests in university-derived science. Lumos Diagnostics is supporting device development under a services agreement. Together, the relationships connect Aptatek’s sensor technology to the engineering, evidence, and manufacturing work required to reach the market.

HomeCheck Is the Larger Bet

PKU is the proving ground, but HomeCheck is the platform thesis. Aptatek says the same aptamer architecture may eventually support other metabolic biomarkers, therapeutic-drug monitoring, and companion diagnostics. The company reports analytical work across more than 10 small molecules, including development exploration involving ammonia and creatinine.

Those programs are not cleared products, and the platform story should not outrun PheCheck. Still, the strategic logic is sound. Many healthcare technologies have moved data collection closer to the patient, while small-molecule measurements remain tied to central laboratories. A reusable reader and adaptable cartridge system could create a repeatable path if the first indication proves clinically and commercially durable.

That is the real Aptatek signal. The company is attempting to move a precise metabolic measurement from a shipping workflow into the rhythm of everyday care. If PheCheck clears the clinical and regulatory bar, the result could be more than a PKU device. It could show how a broader class of laboratory-dependent biomarkers begins to travel less while useful information moves faster.